Trials / Completed
CompletedNCT01137786
Kidney Damage in Patients With Normal eGFR
A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Bracco Diagnostics, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR. Statistical summaries will be presented to analyse the various laboratory tests for the two groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Non ionic contrast media comparator | One time administration for PCI |
| DRUG | Non ionic contrast media comparator | one time administration for PCI |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2010-06-04
- Last updated
- 2013-09-30
- Results posted
- 2013-09-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01137786. Inclusion in this directory is not an endorsement.